Ibutamoren MK-677: human results beyond the hormone rise
Ibutamoren, also called MK-677, is an orally studied small-molecule growth-hormone secretagogue, not a peptide. Human trials show that it can raise growth hormone and IGF-1. They also show why a hormone increase should not be presented as proof of improved cognition, physical function or fat loss.
Identity and formulation
MK-677 and MK-0677 occur in the clinical literature as names for this investigational agent. Product identity should still specify the substance and form rather than relying only on a nickname.
A secretagogue stimulates signaling; it is not somatropin and it is not IGF-1. Those interventions have different exposure and clinical evidence.
What the studies show
The checked human trials span different populations and outcomes. A small body-composition study found increased fat-free mass but no significant fat reduction, and identified impaired glucose handling. Larger studies showed that increased IGF-1 did not reliably translate into the proposed clinical benefits.
| Study and design | Finding | What it does not establish |
|---|---|---|
| MK-677 in adults with obesity
Randomized placebo-controlled eight-week study in 24 men Reading scope: PubMed abstract |
Fat-free mass increased, total and visceral fat did not significantly change, and glucose tolerance was impaired. | Composition changes do not establish greater strength or a favorable long-term risk–benefit balance. |
| MK-0677 after hip fracture
Randomized placebo-controlled trial in older patients Reading scope: PubMed abstract |
IGF-1 increased, but improvement in the principal functional measures was not significantly different. | Biochemical response did not establish meaningful functional recovery. |
| MK-677 in Alzheimer’s disease
Randomized twelve-month trial with 563 assigned patients Reading scope: PubMed abstract |
IGF-1 increased without a significant benefit on the reported clinical progression measures. | The study does not support MK-677 as an Alzheimer’s treatment. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
These results illustrate a useful evidence distinction: target engagement means a biological pathway responded; efficacy means the desired clinical outcome improved. The two cannot be assumed to coincide.
Fat-free mass is also not synonymous with contractile muscle or strength. A body-composition result should remain described in its measured terms.
A case report involving multiple compounds cannot establish which agent caused a change. It should not override controlled single-agent trials or become a general expected-results claim.
Safety context
The small obesity study found impaired glucose tolerance. FDA additionally flags a potential heart-failure safety signal in certain patients; a hormone rise does not resolve those concerns.
Study exposure and units
An oral clinical-study exposure does not supply a personal bodybuilding or anti-aging schedule. Different populations, conditions and durations cannot be combined into a universal regimen.
Peptide-vial reconstitution guidance is misplaced for this orally studied small molecule. A product’s presence in a peptide catalog does not establish an injectable formulation or make peptide-handling instructions applicable.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Check the exact chemical identity and stated form. A report should distinguish ibutamoren from co-sold SARMs or blends, and specify actual content rather than borrow a class-wide claim.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Is MK-677 a peptide or a SARM?
It is a small-molecule growth-hormone secretagogue. Catalog grouping does not change its identity, and it should not be treated as interchangeable with those other categories.
Did higher IGF-1 slow Alzheimer’s progression in the trial?
No. The study demonstrated a biological response without the proposed clinical effect.
Sources
- FDA ibutamoren safety entry (Current official ibutamoren entry)
- MK-677 in adults with obesity (PubMed abstract)
- MK-0677 after hip fracture (PubMed abstract)
- MK-677 in Alzheimer’s disease (PubMed abstract)